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1. Introduction
  Liver failure is the end stage of hepatopathy with 
unfavorable prognosis. Liver transplantation is considered 
as the most effective therapy for liver failure[1,2]. However, 
due to donor liver shortages, immunological rejection, 
difficulties in preserving donor liver, it is difficult to 
perform liver transplantation on a large scale. As an 
effective transitional and alternative therapy, hepatocyte 
transplantation is increasingly attracting much attention for 
it is simpler, effective and has less impact on recipients[3,4]. 
Hopefully, it will become another practical therapy for 
hepatic failure after liver transplantation. Nevertheless, 
searching for suitable hepatocyte sources is one of the keys 
to clinical hepatocyte transplantation[5-10]. We treated two 
patients with liver failure by hepatocyte transplantation 
in January and February, 2009 respectively and achieved 
preliminary results. The transplanted hepatocytes were 
obtained from human allergenic hepatic lobes with benign 
lesions and then were transplanted intrasplenically by 
interventional therapy.
2.  Case report
2.1. Case 1
  Male, 35 years of age, blood type B, was hospitalized 
because of having suffered from hepatitis B for 6 years and 
generalized jaundice for 3 months. Physical examination 
at the time of admission: BP 120/70mmHg, conscious, 
serious icteric skin and sclerae, abdominal distention and 
hydroperitoneum. Total bilirubin (TBIL) 463.13 毺mol/L, 
indirect bilirubin 160.93 毺mol/L, alanine aminotransferase 
(ALT) 69 U/L, aspartate aminotransferase (AST) 118 U/L,
K+ 4.38 mmol/L, Na+ 130.7 mmol/L, Cl- 86.1 mmol/L, 
prothrombin time (PT) 67.3 s, prothrombin activity (PTA) 
12.9%, thrombin time (TT) 30.0 s, HBsAg, HBeAb and HBcAb (+), 
HBV DNA (-), normal AFP, hyaluronicacid (HA) >800 毺g/L.
He underwent adult hepatocyte allotransplantation on 
January 6, 2009. The preparation and process of hepatocyte 
allotransplantation were listed as follows.
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  The sources of donor liver were diseased liver lobes 
acquired from patients who suffered from hepatolithiasis. 
The biopsy showed that there were no obvious cholangitis 
and fibrosis in the liver lobes. The protocol for the 
present study was approved by the regional committee 
of medical ethics. Informed consent was obtained from 
all participants. The surgically resected liver tissue was 
weighed. The hypothermic perfusion/infusion via the 
hepatic artery and the portal vein was carried out at 4 
℃ using University of Wisconsin (UW) solution until 
the color of the liver tissue turned white (Figure 1). 
Afterwards, the hepatic artery and the portal vein were 
completely perfused and rinsed using calcium-free and 
magnesium-free solution /infusionⅠfor 10 min at 37 ℃ 
so as to remove the UW solution remaining inside the 
liver tissue. Then, the liver tissue was fully digested using 
solutionⅡcontaining 0.1% collagenase P at 37 ℃ for 20 
to 30 min until the liver surface turned rhagadiform. The 
digestion was ended using solution Ⅲ (D2Hanks) at 4 ℃
followed by opening the hepatic capsula with scissors 
(Figure 2). Cell filtration was performed using a screen of 
60-mesh sieve and a screen of 120-mesh sieve, followed 
by cell centrifugation at 50 g/min for 5 min and for 3 times 
at 4 ℃, and finally, the hepatocytes were resuspended in 
nutrient fluid. The hepatocyte purity examination by an 
immunocytochemistry test revealed that the purity was up to 
95%. The hepatocellular quantity and viability were tested 
by trypan blue exclusion method (Figure 3). The number 
of transplanted hepatocytes in case 1 was 2.7 伊108, their 
viability was 92%. 
Figure 1. The hepatic lobe after UW perfusion.
Figure 2. Rather lossely organized hepatocytes after collagenase 
digestion treatment.
Figure 3. The cultured hepatocytes.
  The donors underwent femoral artery catheterization 
for super-selective splenic arterial perfusion/ infusion 
transplantation. The end of the inserted catheter passed 
through pancreatic, gastric and colonic ramifications 
of splenic artery (Figure 4) in order to ensure that the 
transplanted hepatocytes were planted inside the donor’s 
splenic pulp and would not affect blood supply of other 
organs. The hepatocyte suspension was infused at 150 mL/h 
via a syringe pump. The methylprednisolone was employed 
to avoid acute allograft rejection. Blood routine tests and 
routine tests of liver function, PT/PTA, cholinesterase, IgA, 
IgG, IgM, C3 and C4 were performed 1 day before the 
transplantation, and 1 day, 7 days, 2 weeks and 4 weeks 
post-transplantation.
Figure 4. Intrasplenic transplantation of hepatocytes via interventional 
therapy.
  The operation was successful. He had improvement in 
hypodynamia, poor appetite and abdominal distention. TBIL 
was 404 毺mol/L one day after the transplantation, PTA and 
cholinesterase increased compared to pre-transplantation, 
and there was no significant difference between blood 
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levels of IgA, IgG, IgM and C3 and C4 prior to and following 
transplantation. On the 6th day after the transplantation, 
TBIL had increased to 471 毺mol/L. The patient became 
restless and disoriented with progressive increases in 
blood/arterial/serum ammonia levels and icteric index. 
Consequently, he decided to give up the treatment and left 
the hospital.
2.2. Case 2
  Male, 28 years of age, blood type A, was hospitalized 
after presenting with generalized jaundice for one week. 
TBIL 319 毺mol/L, direct bilirubin 205 毺mol/L, albumin 
33.68 g/L, ALT 611 U/L. His coagulation function couldn’t 
be tested on the second day after admission and he was 
diagnosed with severe hepatitis and acute liver failure, and 
was treated with therapies such as liver protection, diurese 
and immunomodulation. On the third day after admission 
his TBIL continuously increased and blood/arterial/
serum ammonia level increased. He exhibited clinical 
manifestation of hepatic encephalopathy such as obtundation 
along with ascites, splenomegaly and decompensated 
hepatocirrhosis. The patient underwent hepatocyte 
transplantation 7 days after admission. The process of 
hepatocyte allotransplantation was the same to the Case 1. 
The number of transplanted hepatocytes in case 2 was 7.5
伊108, and their viability was 93%. Prednisone and freeze-
dried human serum albumin were administered to him after 
the transplantation. On the 3rd day after transplantation, he 
had improvement in icteric index and other indexes such 
as coagulation function. TBIL dropped from 489 毺mol/L to 
445 毺mol/L, and the coagulation function indexes returned 
to normal. There was no significant difference between 
blood levels of IgA, IgG, IgM and C3 and C4 before and after 
transplantation. However, his TBIL was up to 629 毺mol/L
one week after the transplantation, and he complained of 
abdominal distending pain on the 11th day. Abdominal 
X-ray plane film indicated that he had an incomplete 
obstruction of small intestine and died of liver failure on 
the 14th day after the transplantation. No postmortem 
examination/autopsy was made after the death.
3. Discussion
  The difficulty in treating hepatic failure is very 
considerable and its mortality is high. Hepatocyte 
transplantation is a cell engineering technology that has 
been developed since the 1970’s[5,6]. It has therapeutic effects 
on acute and chronic hepatic failure and is an effective way 
for the patients who are awaiting donor liver sources and 
in transition to orthotopic liver transplantation[5-10]. The 
technology involves the following steps: first, catheterization 
& perfusion/infusion, isolation, purification and culture 
of the donor’s liver tissue are carried out in situ; then the 
viable hepatocytes with normal cellular function are injected 
into the recipient aiming at partial recovery of the recipent’s 
hepatic secretory and metabolic function and so on. The 
spleen is the optimal site for hepatocyte transplantation 
as it is large in size, and can hold sufficient amounts of 
hepatocytes, and intrasplenic reticular tissue is able to 
capture phagocytes and prevent the transplanted hepatocytes 
from being phagocytized by phagocytes[7,8]. In addition, rich 
blood supply in the spleen offers favorable conditions for the 
hepatocytes’ long-term survival and proliferation. A great 
number of hepatocytes became degenerative, necrositic 
and with reversion differentiation/division in the early stage 
following hepatocyte transplantation. However, hepatocytes 
basically recovered in three months. Hepatic lobules-
like architectures were formed in 5 months, and in about 
1 year, the hepatocytes could line up as paved bricks or 
ropes along with solid reticular fibers in which there were 
glandular tubular architectures appearing, covered with bile 
capillaries of short columnar epithelium.
  It is a significantly important research project to search for 
suitable hepatocytes for transplantation nowadays. Although 
heterogenic hepatocytes like swine hepatocytes are a rich 
source, there are risks of zoonoses and relatively serious 
immunological rejection if they are applied for hepatocyte 
transplantation in humans; immortalized hepatocytes have 
unlimited proliferation ability, but their carcinogenic risk 
limits their clinical application to a certain degree. Adult 
hepatic stem cells (oogonia/hepatic stem cells) are capable 
of differentiating into mature hepatic cells, but, currently 
there are no effective methods available for identifying and 
culturing this type of cells. For human fetal hepatocytes and 
hepatic stem cells, social ethics restricts their application, 
although some people have transplanted them into human 
bodies. Further research is required to evaluate their 
efficacy for transplantation. Nowadays, primary human 
hepatocytes are the most suitable cells to approach/meet 
requirements for clinical application[9]. However, they are 
unable to proliferate in large quantities and be applied in 
emergencies due to source shortages.
  There have been no reports available in the literature about 
using primary human hepatocytes from liver tissue obtained 
by hepatectomy on patients with benign hepatic lesions 
for hepatocyte transplantation. In this study, the viable 
primary human hepatocytes obtained from the hepatic lobes 
surgically resected from the two patients with hepatolithiasis 
were intrasplenically transplanted via interventional 
therapy, which expanded hepatocellular sources. If 
adequate amounts of viable adult hepatocytes can be gained 
from surgically resected liver tissue with benign lesions, 
shortages of hepatocyte sources will be radically improved. 
Further, fewer issues regarding ethics, medical risks and 
so on are involved in this practice. To ensure that adequate 
amounts of hepatocytes of high purity and good viability 
could be isolated and acquired, we modified methods of 
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hepatectomy and hepatocyte isolation in the study. We 
performed left liver lobecotomy by adopting highly selective 
regional vascular clamping in which the hepatic artery of 
the left lobe of liver, the branches of the portal vein and left 
hepatic vein were isolated and retained at first, and then the 
preparatory catheterization was done, the cutting surface 
of left hepatic lobe was separated and cut by clamping 
technique, the vascular branches on both sides of the 
hepatic cutting surface were ligated, and the biliary duct 
on the cutting surface of the left hepatic lobe was closed 
by ligation. Shortly afterwards, the surgically resected liver 
tissue underwent hypothermic perfusion/infusion via the 
hepatic artery and the portal vein at 4℃ using UW solution 
until the color of the liver tissue turned white. We changed 
conventional two-step isolation technique of hepatocytes 
into a three-step collagenase isolation technique of 
hepatocytes. Preventive antibiotics were administered to the 
donors, and samples of the bile was obtained for bacterial 
culture during transplantation, the common bile duct was 
not opened when liver resection was performed, which 
aimed to greatly reduce the warm ischemia time of the donor 
liver tissue, prevent intrahepatic bile from contaminating 
the hepatocytes and make their effective acquisition rate, 
purity and viability meet requirements for hepatocyte 
transplantation.
  After the acquired hepatocytes were transplanted in the 
spleen via splenic artery, and the state of illness of the two 
recipents took a favorable turn to a certain degree, their 
hepatic function improved. Neither of the two patients 
suffered from bleeding, splenic infarctions or infarctions of 
extrasplenic organs, and they didn’t suffer from infection 
and other complications from the procedure. There was no 
increase in IgA, IgG, IgM and C3 and C4 which indicated that 
no obvious allograft rejection was provoked in the recipient 
bodies after hepatocyte transplantation. Limited observation 
showed that it is technically feasible and of some clinical 
efficacy to acquire viable primary human hepatocytes 
from surgically resected liver tissue with benign lesions 
and to transplant them intrasplenically. The transplanted 
hepatocytes may provide the recipients with support in 
terms of liver function, and therefore, bridging the time 
between the recipient’s native liveregeneration and hepatic 
transplantation.
  The reasons that the recipients’ serum bilirubin level 
rose to some extent one week after transplantation were 
probably related to: 1) The transplanted number of 
hepetocytes was much lower than the theoretical effective 
amount, 109, and as a result, the hepatocytes’ functional 
compensation after transplantation was not completed, and 
therefore, it is difficult to radically reverse the recipients’ 
status of hepatic failure; 2) Although the transplanted 
hepatocytes could partially serve as a substitute for the 
recipients’ liver function in a short period of time and 
improved it to a certain degree, the number of viable and 
functional hepatocytes were reduced and more transplanted 
hepatocytes became apoptotic as time went by; 3) Further 
studies are required on whether there is immunological 
rejection or not, and to what degree. Therefore, in terms 
of maintaining and constantly improving the recipients’ 
liver function, it is vital importance to seek methods to 
make transplanted hepatocytes proliferate and become less 
apoptotic and how to establish hepatocyte banks of a variety 
of donor hepatocyte sources with the intention of providing 
adequate amounts of functional primary human hepatocytes 
from multiple donors for a single recipient.
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